The University of Bristol and National Health Service (NHS) Blood and Transplant have developed a new method to manufacture red blood cells (RBC).

The researchers have produced lines of immortalised cells to allow manufacture of RBC in a more efficient scale.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It is expected that upon successfully clinical trial evaluation of the research results, a safe source can be established for transfusions for people with rare blood types, as well as in areas where blood supplies are deficient or unsafe.

The previous method of growing donated stem cells into mature RBC is reported to generate small number of mature cells and to need repeat donations.

The new reproducible method aims at addressing this concern and facilitates the production of immortalised erythroid cell lines from adult stem cells.

The premature red cells can then be cultured indefinitely on a large-scale prior to differentiation into mature RBC.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

NIHR Blood and Transplant Research Unit in Red Cell Products director professor Dave Anstee said: “The patients who stand to potentially benefit most are those with complex and life-limiting conditions like sickle cell disease and thalassemia, which can require multiple transfusions of well-matched blood.

“The intention is not to replace blood donation but provide specialist treatment for specific patient groups.”

“The intention is not to replace blood donation but provide specialist treatment for specific patient groups.”

The NIHR Blood and Transplant Research Unit in Red Cell Products is a collaboration between the University of Bristol and NHS Blood and Transplant.

Cultured at the University of Bristol and at NHS Blood and Transplant’s Filton site, the red cells will be  investigated in different clinical trials.

Set to start by the end of this year, the first trial will utilise manufactured red cells from stem cells in a normal blood donation.


Image: The immortalised early erythroid cells. Photo: courtesy of University of Bristol.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact